CLBT
The market hit the brakes
Cellebrite's stock got tossed around like it forgot its lunch in the fridge — down 33% after earnings, even though the business still looks pretty sturdy underneath the hood. The issue wasn’t some disaster movie. It was more of a messy quarter: ARR and revenue missed guidance, Inseyets conversions moved slower than hoped, and management shuffled the deck.
The good stuff didn’t vanish
Here’s the part the selloff might be ignoring: Cellebrite is still throwing off 80%+ gross margins and about 28% free cash flow. That’s not the profile of a company in flames. It’s more like a high-quality engine that coughed on one hill climb.
The catch: execution now matters more
The bear case isn’t nonsense, though. Slower conversions for Inseyets and rising stock-based compensation can make investors twitchy, especially when growth is supposed to be the whole point. But management is still guiding for high-teens revenue growth, which says the story is more “prove it” than “pack it up.”
Big picture
If you’re an investor, this is the classic market overreaction debate: is the stock reflecting a real crack in the model, or just a quarter where expectations got ahead of execution? Right now, the answer looks annoyingly somewhere in the middle.